TAK1-NFkB inhibitors (Emory University/Roswell Park Comprehensive Cancer Center)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameTAK1-NFkB inhibitors (Emory University/Roswell Park Comprehensive Cancer Center)
Drug Alias Name5Z-7-oxozeaenol analogs (Emory University)TAK-1 inhibitors (Emory University)TAK1-NFkB inhibitors (Emory University/Roswell Park Cancer Institute)HDAB-006HDAB-001
ClassificationSmall molecules
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsAnticancer protein kinase inhibitorsTGF-β activated kinase-1 inhibitors
TargetsTGF-β activated kinase-1Nuclear factor NF-kappa-B complex
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEmory University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoswell Park Comprehensive Cancer CenterEmory University
Active IndicationsN/A
Inactive IndicationsInflammationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A